# Allogeneic Bone Marrow Mesenchymal Stem Cells for Patients With Interstitial Lung Disease (ILD) & Connective Tissue Disorders (CTD)

> **NCT03929120** · PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 10 (actual)

## Conditions studied

- Interstitial Lung Disease
- Connective Tissue Diseases

## Interventions

- **BIOLOGICAL:** Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)

## Key facts

- **NCT ID:** NCT03929120
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-05
- **Primary completion:** 2021-07-27
- **Final completion:** 2022-02-02
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2023-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03929120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03929120, "Allogeneic Bone Marrow Mesenchymal Stem Cells for Patients With Interstitial Lung Disease (ILD) & Connective Tissue Disorders (CTD)". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT03929120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*